Clinical trials: Peritoneum Cancer
Fallopian Tube Cancer, Ovarian Cancer
Irofulven in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Peritoneal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of irofulven in treating patients who have recurrent or…
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00019552
- Testing
- irofulven
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Peritoneal Carcinomatosis, Colon Cancer
Clinical Trial on HIPEC With Mitomycin C in Colon Cancer Peritoneal Metastases (GECOP-MMC)
The aim of this study is to assess whether there are differences in PERITONEAL RECURRENCE in patients with Colon Cancer Peritoneal Metastases treated with complete surgical resection and systemic chemotherapy, with (Group 1) or…
- Trial name
- GECOP-MMC (NCT05250648)
- Testing
- complete cytoreductive surgery plus HIPEC with Mytomicin C for 90 minutes, complete cytoreductive surgery without HIPEC
- Where
- 31 sites in Spain
- Volunteers
- 216 people
- Sponsor
- Hospital Universitario de Fuenlabrada
Urinary Bladder Neoplasms, Carcinoma, Transitional Cell
A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors
The purpose of the study is to evaluate the safety and to define the Maximal Tolerated Dose (MTD) or the Maximal Administered Dose (MAD) of oral azacitidine as a single agent and in combination with carboplatin (CBDCA) or…
- Conditions
- Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ovarian Neoplasms, Fallopian Tube Neoplasms
- Trial name
- NCT01478685
- Testing
- CC-486, Carboplatin, ABI-007
- Where
- 13 sites in United States, France and 2 more
- Volunteers
- 169 people
- Sponsor
- Celgene
Peritoneal (Metastatic) Cancer, Colorectal Cancer
Biopsy-Resection Agreement of Peritoneal Histopathological Growth Patterns in Colorectal Peritoneal Metastases: A Prospective Observational Pilot Study
his prospective, single-center observational pilot study evaluates whether peritoneal histopathological growth patterns can be assessed on limited excisional biopsies obtained during staging laparoscopy in adults with suspected…
- Conditions
- Peritoneal (Metastatic) Cancer, Colorectal Cancer, Colorectal (Colon or Rectal) Cancer, Histopathological Growth Patterns (HGPs)
- Trial name
- PROCPHGP (NCT07474025)
- Where
- 2 sites in Belgium
- Volunteers
- 30 people
- Sponsor
- Jules Bordet Institute
Peritoneal Carcinomatosis
A Nomogram to Predict Major Postoperative Complications After Cytoreductive Surgery and HIPEC Based on Pre and Peroperative Criteria: Which Patient Require Intensive Monitoring?
In this study, the investigators tend to highlight pre and peroperative factors that predict major postoperative complication after a surgery for resection of peritoneal carcinomatosis.
- Trial name
- NCT05547568
- Testing
- Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy
- Where
- France
- Volunteers
- 219 people
- Sponsor
- CHU de Reims
Fallopian Tube Cancer, Ovarian Cancer
Chemotherapy in Treating Patients With Recurrent, Metastatic, or Unresectable Ovarian, Fallopian Tube, or Peritoneal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of DX-8951f in treating patients who have recurrent…
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00004060
- Testing
- exatecan mesylate
- Where
- United States
- Sponsor
- Daiichi Sankyo
Colorectal Neoplasm, Metastasis
Adjuvant HIPEC to Prevent Colorectal Peritoneal Metastases in High-risk Patients
The prognosis of peritoneal metastases from colorectal cancer has recently improved with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC).
- Trial name
- NCT02575859
- Testing
- adjuvant HIPEC, surgery
- Volunteers
- 20 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Ovarian Cancer, Genitourinary (GU) Tumors
A Phase 2 Study of the IDO Inhibitor Epacadostat Versus Tamoxifen for Subjects With Biochemical-recurrent-only EOC, PPC or FTC Following Complete Remission With First-line Chemotherapy
This is an open-label, randomized, phase 2 study of an IDO inhibitor, INCB024360 (epacadostat) versus tamoxifen in biochemical recurrent only ovarian cancer patients following complete remission with first-line chemotherapy.
- Trial name
- NCT01685255
- Testing
- Epacadostat, tamoxifen
- Where
- 49 sites in United States, Australia and 4 more
- Volunteers
- 83 people
- Sponsor
- Incyte Corporation
Fatigue, Malignant Ovarian Mixed Epithelial Tumor
Acetyl-L-Carnitine Hydrochloride in Preventing Peripheral Neuropathy in Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy
This randomized phase III trial studies how well acetyl-L-carnitine hydrochloride works compared to a placebo in preventing peripheral neuropathy in patients with recurrent ovarian epithelial cancer, primary peritoneal cancer, or…
- Conditions
- Fatigue, Malignant Ovarian Mixed Epithelial Tumor, Neuropathy, Neurotoxicity Syndrome
- Trial name
- NCT01492920
- Testing
- Acetyl-L-Carnitine Hydrochloride, Questionnaire Administration, Quality-of-Life Assessment
- Sponsor
- Gynecologic Oncology Group
Ovarian Cancer
Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care Maintenance Treatment After First-line (1L) Platinum-based Chemotherapy in Participants With Ovarian Cancer
This Phase 3 study will be conducted in different countries around the world with up to approximately 602 participants. The purpose of this study is to evaluate how well Rina-S alone or in combination with an approved, standard…
- Trial name
- RAINFOL™-10 (NCT07859215)
- Testing
- Rina-S, Bevacizumab
- Volunteers
- 602 people
- Sponsor
- Genmab
Chylous Ascites, Abdominal Neoplasm
Oral Iohexol in the Management of Chylous Ascites After After Retroperitoneal or Extended Lymphadenectomy
The goal of this clinical trial is to assess the effectiveness of oral iohexol in the treatment of postoperative chylous ascites. It will also learn about the safety of oral iohexol.
- Conditions
- Chylous Ascites, Abdominal Neoplasm, Pelvic Neoplasms, Retroperitoneal Lymph Node Metastasis
- Trial name
- NCT06820320
- Testing
- oral iohexol, Lymphangiography and Embolization
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Breast Cancer, Ovarian Cancer
Pilot Study of Durvalumab and Vigil in Advanced Women's Cancers
In this study, the researchers want to learn more about Vigil and durvalumab in advanced women's cancers: 1) how much of Vigil in combination with durvalumab (MEDI4736) can be given with an acceptable level of side effects, 2)…
- Conditions
- Breast Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
- Trial name
- NCT02725489
- Testing
- Vigil, Durvalumab
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Mary Crowley Medical Research Center
Fallopian Tube Cancer, Ovarian Cancer
S0904: Docetaxel With or Without Vandetanib in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00872989
- Testing
- docetaxel, vandetanib
- Where
- 137 sites in United States
- Volunteers
- 129 people
- Sponsor
- SWOG Cancer Research Network
Ovarian Cancer
A Study of Bevacizumab (Avastin) in Neoadjuvant Therapy in Participants With International Federation of Gynecology and Obstetrics (FIGO) Stage IIIC/IV Ovarian, Tubal, or Peritoneal Cancer, Initially Unresectable
This randomized, open-label study will evaluate the efficacy and safety of neoadjuvant bevacizumab in participants with initially unresectable, FIGO stage IIIC/IV ovarian, tubal, or peritoneal cancer.
- Trial name
- ANTHALYA (NCT01739218)
- Testing
- Carboplatin, Paclitaxel, Bevacizumab
- Where
- 15 sites in France
- Volunteers
- 99 people
- Sponsor
- Hoffmann-La Roche
Pneumoperitoneum
CO2 Absorption During Laparoscopy
CO2 absorption from the pneumoperitoneum increases over time during laparoscopic procedures. Adding 4% of oxygen to the carbon dioxide was shown in rabbits to decrease CO2 resorbtion through prevention of mesothelial hypoxia.
- Trial name
- NCT01340989
- Testing
- alteration of the insufflation gas, full conditioning, standard pneumoperitoneum
- Where
- Belgium
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University Hospital, Gasthuisberg
Fallopian Tube Cancer, Ovarian Cancer
S9912 Combination Chemo in Stage III Ovarian Cancer,
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
- Trial name
- NCT00003896
- Testing
- cisplatin, liposomal doxorubicin, paclitaxel
- Where
- 104 sites in United States
- Volunteers
- 68 people
- Sponsor
- SWOG Cancer Research Network
Colorectal Cancer, Ovarian Cancer
An Audit of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
Peritoneal carcinomatosis is a common event in the natural history of colorectal and other digestive tract cancers. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) provides a promising…
- Conditions
- Colorectal Cancer, Ovarian Cancer, Peritoneal Disease
- Trial name
- NCT02754115
- Testing
- Hyperthermic intraperitoneal chemotherapy
- Where
- India
- Volunteers
- 400 people
- Sponsor
- Tata Memorial Centre
Epithelial Ovarian, Fallopian Tube
TAME: A Pilot Study of Weekly Paclitaxel, Bevacizumab, and Tumor Associated Macrophage Targeted Therapy (Zoledronic Acid) in Women With Recurrent, Platinum-resistant, Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
This is a randomized pilot trial of weekly paclitaxel and bevacizumab with or without zoledronic acid in women with platinum-resistant epithelial ovarian cancer with 1-2 prior regimens for recurrence.
- Conditions
- Epithelial Ovarian, Fallopian Tube, Primary Peritoneal Cancer
- Trial name
- NCT05053750
- Testing
- Paclitaxel/Bev (control), Paclitaxel/Bev + ZA (experimental)
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer Stage III, HER2-positive Metastatic Breast Cancer
Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors
The objective of this study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of BL-M17D1 in patients with HER2-Expressing or HER2-Mutant Advanced or Metastatic Solid Tumors.
- Conditions
- Breast Cancer Stage III, HER2-positive Metastatic Breast Cancer, Unresectable Breast Carcinoma, Her2-Positive
- Trial name
- NCT06714617
- Testing
- BL-M17D1
- Where
- 9 sites in United States
- Volunteers
- 3 people
- Sponsor
- SystImmune Inc.
Advanced Gastric Cancer With Serosal Invasion
Intraperitoneal Chemotherapy and Systemic Chemotherapy Versus Systemic Chemotherapy After Curative Resection of Serosa-positive Gastric Cancer
Intraperitoneal chemotherapy as an adjuvant treatment modality is designed to eradicate intraperitoneal free tumor cells that can be a source of peritoneal carcinomatosis.
- Trial name
- EPIC-GC (NCT02205008)
- Testing
- surgery, adjuvant systemic chemotherapy, Early postoperative intraperitoneal chemothgerapy
- Where
- South Korea
- Volunteers
- 230 people
- Sponsor
- Kyungpook National University Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.